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Noroviruses Represent a Significant Worldwide
Disease Burden
Noroviruses (NoVs), members of the Calicivirus family, are
small, positive-polarity RNA viruses and the most important cause
of human foodborne viral gastroenteritis worldwide. These viruses
cause gastrointestinal disease, resulting in recurrent bouts of
vomiting and diarrhea that typically last 24–48 hours. NoVs are
transmitted via the fecal–oral route, most commonly through
infected food or water or person-to-person contact, and result in
267 million infections [1] and over 200,000 deaths each year,
mostly in infants and the elderly [2]. Vaccines and therapeutics are
under development but face considerable challenges as there is no
cell-culture system or small-animal model for human disease, and
these viruses are highly heterogeneous and undergo antigenic
variation in response to human herd immunity, further compli-
cating our understanding of the complex immune interactions that
regulate susceptibility and disease.
Despite these limitations, considerable progress has been made
in understanding NoV adaptive immunity. This article discusses
our current understanding of virus–host immune interactions that
regulate host susceptibility, virus evolution, and protective
immunity. We focus on virion structure, serologic relationships
among strains, molecular mechanisms governing the changing
antigenic landscape of human NoVs over time, cellular immunity,
and relationships between human herd immunity, antigenic
variation, and histoblood group antigen (HBGA) recognition,
which are predicted to drive the emergence of new outbreak
strains that target different human populations and/or afford
escape from protective herd immunity. We discuss the implications
of these observations on future vaccine design.
Specific Host and Virus Genetic Factors Influence
NoV Susceptibility, Evolution, and Immunity
NoVs are divided into five genogroups (GI-GV), which differ by
.60% based on capsid sequence [3], and GI and GII NoVs cause
the majority of human disease (Figure 1A–C). Genogroups are
further divided into genotypes, which differ by about 40%, with
GI.1 as the prototypic ‘‘Norwalk’’ genotype and the GII.4 NoVs as
the genotype responsible for the majority (80%) of outbreaks [4].
GII.4 NoVs in particular appear to accommodate a high level of
sequence diversity and undergo positive selection in key surface-
exposed residues, likely allowing for escape from herd immunity
[1,5]. Differences in evolution rates among different GI and GII
NoVs have been attributed to receptor switching and effective
population size, VP1 sequence space and structural plasticity,
duration of herd immunity, and replication fidelity [1,6–9].
HBGAs are a diverse family of carbohydrates expressed on
mucosal surfaces where they serve as binding ligands and putative
receptors for NoV. HBGAs are differentially expressed in
individuals and binding to specific HBGAs varies by NoV strain.
Expression of most HBGAs on mucosal tissues is dependent on the
presence of a functional FUT2 gene, which codes for a
fucosyltransferase that adds side chains to a precursor molecule.
About 20% of people do not encode a functional FUT2 gene and
are considered ‘‘non-secretors’’ (Figure 1D). Non-secretors are
resistant to GI.1 (Norwalk virus) infection [10]; however, some
other NoV strains are known to infect non-secretors, probably by
attachment to Lewis carbohydrates [11–14]. GII.4 strains may
predominate because the epidemic strains bind A, B, and O
secretors, representative of 80% of the population. Antibodies that
block virus binding to HBGA are considered ‘‘blockade antibod-
ies’’ and are predicted to be neutralizing. Importantly, high
prechallenge blockade antibody titers correlate with protection
from infection following primary challenge and vaccination [15].
The development of more human challenge strains and thera-
peutic antibodies will be key for illuminating the complex
relationships among HBGA affinity, host susceptibility, short and
long-term immunity outcomes, and the mechanism of action by
which blockade antibodies prevent infection.
NoV Immunity: Humoral Immune Response
A handful of human challenge studies provide insight into the
potential for protective immunity to NoVs. Short-term immunity
has previously been established for GI.1 viruses [16], and a recent
vaccine study found that intranasal vaccination with GI.1 VLPs
protected against disease three weeks post vaccination [17]. The
existence of long-term immunity is more controversial; however,
multiple studies found protective responses against GI.1 were
present six months after challenge in some but not all individuals
[15,17,18]. Mucosal IgA responses to Norwalk virus indicate that
an early salivary IgA response (days 1–5), rather than a late
response, correlated with protection from infection in secretor-
positive individuals; this suggests that previous strain exposure
elicited a protective memory response against the challenge strain
[10]. The rapid epidemic GII.4 strain replacement by new isolates
every 3–7 years is consistent with protective, long-term herd
immunity in a substantial portion of the population [19].
GI and GII antibodies are high in acute sera, while cross-
blockade patterns are genogroup-specific [15,20]. Sera against GI
outbreaks are cross-blocking within the genogroup and are
Citation: Debbink K, Lindesmith LC, Donaldson EF, Baric RS (2012) Norovirus
Immunity and the Great Escape. PLoS Pathog 8(10): e1002921. doi:10.1371/
journal.ppat.1002921
Editor: Richard C. Condit, University of Florida, United States of America
Published October 18, 2012
Copyright:  2012 Debbink et al. This is an open-access article distributed
under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: This work was supported by grant AI056351 from the National
Institutes of Health, National Institute of Allergy and Infectious Diseases (to RSB),
and a Gillings Innovation Laboratory award from the UNC Gillings School of
Global Public Health (to EFD). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests
exist.
* E-mail: rbaric@ad.unc.edu
PLOS Pathogens | www.plospathogens.org 1 October 2012 | Volume 8 | Issue 10 | e1002921
sometimes higher for a heterologous strain after infection [6,20];
however, the blocking response does not extend to GII NoVs [21].
In contrast, sera against GII outbreaks have much higher strain-
specific homologous responses and not broad GII blocking
responses [22,23]. These studies are complicated by complex
preexposure histories in human populations, coupled with a very
Figure 1. NoV Genetic Diversity, Structure, and Binding Ligand. 1A: NoV genome schematic. The NoV genome encodes three open
reading frames. ORF 1 encodes the nonstructural proteins (blue); ORF 2 encodes VP1, the major capsid protein (purple); and ORF 3 encodes VP2, the
minor capsid protein (green). VP1 is further divided into the shell, which forms the base of the virion (teal); the P1 subdomain, which forms a stalk-like
projection from the surface (orange); and the P2 subdomain, which is the most variable and surface-exposed area of the virion, contains ligand
binding sites, and interacts with potentially neutralizing antibodies (red). 1B: NoV phylogenetic tree. NoVs are divided into five genogroups.
Genogroups 1 (pink) and 2 (orange) cause the majority of human disease. Genogroups are further divided into genotypes. Genotype GII.4 NoVs (red
bracket) account for ,80% of outbreaks. Genotype GI.1 NoVs are the prototypic Norwalk viruses. 1C: NoV capsid protein (VP1) cryo EM image.
Colors correspond approximately to the shell (teal), the P1 subdomain (yellow/orange) and the P2 subdomain (red). 1D. Secretor/non-secretor
phenotype pathways. Enzymes (Secretor or Lewis) add specific modifications to a precursor molecule. Individuals without a functional FUT2 gene
cannot express HBGAs from the left branch of the pathway (left of the dotted line) on mucosal surfaces. For those without a functional FUT2 gene
(non-secretors), the precursor molecule can still be modified by the Lewis enzyme to make Lewis a antigen (branch on the right side of the dotted
line).
doi:10.1371/journal.ppat.1002921.g001
PLOS Pathogens | www.plospathogens.org 2 October 2012 | Volume 8 | Issue 10 | e1002921
poor understanding of the serologic relationships among strains.
Using mouse sera targeting single strains, reactivity across GI
genotypes is about 5–10% of the homotypic response and is less
than 5% between genogroups [24]. Simultaneous exposure of
rodents or rabbits to multiple strains significantly boosts cross-
reactive antibody responses, suggesting that complex patterns of
cross reactivity may exist within multiple GI or multiple GII
genotypes or that repeat and/or multivalent exposure selects for
high-affinity antibodies that tolerate variation within target
epitopes [24,25].
Classic approaches for mapping epitopes cannot be applied to
NoV because of the lack of a cell culture system for isolating
antibody escape mutants. For G1 NoVs, point and deletion
mutations have identified regions of VP1 targeted by antibodies
[26,27]. For GII.4 strains, epitope mapping has been done
primarily by using bioinformatics approaches to identify rapidly
evolving amino acid residues and exchanging these regions
between strains [7–9,28] (Figure 2B). This has allowed for precise
mapping of key residues that drive antigenic change in response to
human and rodent antibody binding and blockade responses.
These mapping studies define key sites of antigenic change;
however, the actual antibody binding epitope is usually confor-
mational and likely includes proximal conserved and varying
residues that contribute to escape from human herd immunity. A
recent crystallography study mapped the binding of a cross-
reactive GII monoclonal antibody in complex with a GII.10 P
particle to a highly conserved, occluded site within the P1
subdomain, suggesting that the NoV P domain may accommodate
high conformational flexibility [29].
Monoclonal antibodies that target distinct GII.4 strains
demonstrate that antigenic variation is high and these strains are
evolving in response to human herd immunity. These data also
support the hypothesis that many human and mouse blockade
monoclonal antibodies appear to target similar varying epitopes in
GII.4 VLPs. Three blockade epitopes have been confirmed,
designated A, D, and E [5,7–9] (Figure 2A, C, D). Epitope A is
substantially recognized by human polyclonal sera; Epitope D
(residues 393–395) is especially interesting because this region also
alters HBGA binding affinity [6,8,14]. Importantly, New Orleans
2009 and its recent derivatives demonstrate continued evolution in
the major blockade epitopes, suggesting escape from GII.4–2006
herd immunity. These data support the hypothesis that antigenic
changes that result in escape from herd immunity may also drive
changes in HBGA affinities, altering population susceptibility
patterns. While multiple blockade epitopes change over time,
conserved, unmapped GII.4 blockade epitopes also exist [5].
While evidence for cross-blockade GII epitopes is limited [21],
cross-blockade epitopes may be more common for GI strains,
explaining the reduced frequency of disease patterns seen in
human populations [20]. No GI or cross-GI and GII antibody
blockade epitopes have been mapped, signaling an important
priority for future studies. To further characterize the complexity
of the molecular mechanisms driving antigenic variation, addi-
tional crystal structures in complex with strain, genotype, and
genogroup-specific antibodies are needed to define complete
epitopes, tease apart overlapping epitopes, and map the exact
residues comprising important cross-reactive and cross-blockade
epitopes.
NoV Immunity: Cellular Immune Response
The role that T cells play in controlling NoV infection is
complex and not well characterized. Human NoV infection or
vaccination elicits a primarily CD4+ Th1 response, leading to
increased secretion of IFN-gamma and IL-2 [13,20]. One study
using human-derived PBMCs found that T cell responses were
more cross-reactive between GII strains with higher antigenic
relatedness [13], while another study found that T cell responses
toward alternate GI strains were more robust than the immunizing
GI strain in some individuals [20]. Additional studies using a wider
array of genotypes are needed to further characterize T cell
responses and their relationships in controlling human infection.
Important Considerations for NoV Therapeutic
Design
NoVs are the primary cause of acute gastroenteritis and are
responsible for hundreds of thousands of deaths worldwide, mostly
in infants in the developing world. In developed countries, the
elderly are particularly vulnerable to life-threatening infections [6].
Although few people die from NoV in developed countries,
economic costs of NoV outbreaks are high due to lost productivity,
lost wages, and decontamination costs; a single outbreak in a
hospital setting can cost upwards of US$650,000 [30]. Addition-
ally, NoV outbreaks in military settings pose security risks.
Development of a vaccine would reduce economic costs, aid
military operations, and save lives; however, development of a
NoV vaccine faces considerable obstacles given the strain
heterogeneity, likely necessitating a multivalent formulation. While
it is encouraging that multivalent vaccines appear to elicit robust
responses against strains that are not included in the cocktail [24],
the molecular mechanisms governing these responses must be
defined for rational vaccine design. There are several other
important considerations that would aid in design of such a
vaccine:
1) Mapping and determining the relative contribution of each
blockade epitope as a correlate of short or long-term
protective immunity is key to successful vaccine design,
especially against strains that evolve over time. Mapping
conserved intra- or intergenotype epitopes may uncover
more broadly acting therapeutic targets.
2) Additional human challenge studies with both GI and GII
NoVs need to be conducted to more fully understand how
long protective immunity lasts among different genogroups
and genotypes.
3) The impact of preexposure history and temporal and
phylogenetic space on contemporary strain vaccine immune
responses will need to be clarified.
4) The contribution of T cell responses (CD4+, CD8+, Th17)
in protective immunity will need to be further elucidated.
5) The role of innate immunity in viral pathogenesis and in
short- and long-term herd immunity will need to be
examined. Areas of the capsid undergoing positive selection
over time in rapidly evolving NoV genotypes will need to be
continuously monitored in order to keep abreast of novel
surface variation that may lead to escape from herd
immunity and emergence of new pandemic strains.
6) The potential effects a vaccine would have on the
evolutionary dynamics of emerging NoV strains will need
to be clarified.
Addressing these questions will not only allow for better design
of NoV vaccines and immunotherapeutics, but will inform
strategies for minimizing the global disease burden of other highly
variable and highly pathogenic human viruses.
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Figure 2. GII.4 NoV Variation over Time. 2A: GII.4 blockade epitopes. Three blockade epitopes have been identified in GII.4 NoVs. Epitope A
(residues 294, 296–298, 368, and 372; green), Epitope D (residues 393–395; orange), and Epitope E (residues 407, 412–413; yellow) all map to the P2
subdomain on the surface of the virion. The HBGA interaction sites are shown in black. 2B: GII.4 P2 subdomain variation over time. Colored
residues indicate change over time since 1974; changes present in 1987 = yellow, 1997 = red, 2002 = teal, 2004 = green, 2005 = orange, 2006 = purple,
2009 = blue, HBGA interaction sites = black, carbohydrates = white sticks. 2C: GII.4 NoV variation over time in blockade-epitope regions. GII.4
NoV blockade epitopes undergo change over time, likely in response to human herd immunity. Colors indicate in which outbreak strain a particular
residue change originated. 2D: Mapping of GII.4 variation over time in blockade-epitope regions. Each VLP shows areas within blockade
epitopes that change over time. Yellow indicates differences from 1974 present in 1987, 1997 = red, 2002 = teal, 2004 = green, 2005 = orange,
2006 = purple, and 2009 = blue. These blockade epitopes have continued to evolve in new outbreak strains since 2009.
doi:10.1371/journal.ppat.1002921.g002
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